Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). It focuses on products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions.

 
News
 
 
Language
 
Tuesday, September 20. 2016
 
Basel, Switzerland, September 20, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license and distribution agreement with Unimedic Pharma AB (Unimedic) for Basilea's antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in the Nordic countries, including Sweden, Denmark and Norway, and Finland.
 
more...
 
Thursday, September 15. 2016
 
  • Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan
  • Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties

 
more...
 
Tuesday, September 13. 2016
 
Basel, Switzerland, September 13, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a supply, distribution and license agreement with Grupo Biotoscana S.L., (GBT) for Basilea's antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in 19 countries in Latin America including Brazil, Mexico, Argentina and Colombia.
 
more...
 
Tuesday, September 06. 2016
 
Basel, Switzerland, September 6, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the first patient has been dosed in a new phase 1/2a continuous infusion study with its tumor checkpoint controller BAL101553 in patients with advanced solid cancers. Continuous infusion with portable pumps is an established mode of drug administration used for the treatment of certain cancers.
 
more...
 
Info
 
 
 

Quick links:

Investor calendar
Upcoming events
 


News subscription
Press releases via e-mail
 


French Sunshine Act
Transparence des liens d’intérêt